Telomerase activity inhibiting peptide and manufacturing method and application thereof
The present invention provides a telomerase activity inhibiting polypeptide. The expression of the polypeptide in tumor cells can inhibit significantly tumor cell telomerase activity, tumor cell growth, and lead to the death of such cells. The present invention further provides a preparation method for the polypeptide and an application thereof in targeted treatments of tumors.
1. A fusion protein, comprising:
(a) a polypeptide consisting of the amino acid sequence at positions n-328 of SEQ ID NO: 2, wherein n is an integer from 255 to 290; and
(b) at least one functional protein linked, directly or via a linker peptide, via a peptide bond to the N-terminus of the polypeptide of (a),
wherein the functional protein comprises 5-500 amino acids,
wherein the linker comprises 1-20 amino acids.
2. An isolated polynucleotide, characterized in that the polynucleotide comprises a nucleotide sequence that encodes the polypeptide of claim 1 .
3. A vector, characterized in that the vector comprises the polynucleotide of claim 2 .
4. A genetically engineered host cell, characterized in that the genetically engineered host cell comprises the vector of claim 3 .
5. A composition, wherein the composition comprises the fusion protein of claim 1 .
6. The composition of claim 5 , characterized in that the composition further comprises a material selected from the following: a protein activity promoter, a protein activity stabilizer, and a protein half-life extending preparation.
7. The composition of claim 5 , further comprising a pharmaceutically acceptable carrier.
8. A method for preparing the composition of claim 7 , comprising: mixing an effective amount of the fusion protein with the pharmaceutically acceptable carrier.
9. A kit, characterized in that the kit comprises the fusion protein of claim 1 .
10. The composition of claim 6 , further comprising a pharmaceutically acceptable carrier.
11. A method for preparing the composition of claim 10 , comprising: mixing an effective amount of the composition with the pharmaceutically acceptable carrier.
12. A kit, characterized in that the kit comprises the composition of claim 6 .
13. A kit, characterized in that the kit comprises the composition of claim 7 .
14. The fusion protein of claim 1 , wherein the at least one functional protein is selected from: a membrane-penetrating protein, a tag protein, a reporter protein, or human IgG1:Fc fragment.
15. The fusion protein of claim 14 , wherein the membrane-penetrating protein is Trans-Activator of Transcription (TAT), penetratin, a signal peptide, murine vascular endothelial-cadherin protein (pVEC), transportan, an amphiphilic peptide, or a peptide of nine arginines (Arg9).
16. The fusion protein of claim 14 , wherein n is 290.